You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Management of advanced HIV disease

From: Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa

  N (%)
ART
 Components of ART regimena
  NRTI backbone
   TDF + 3TC or FTC 160 (95.2)
   AZT + 3TC or FTC 8 (4.8)
  EFV-based regimenb 141 (83.9)
  NVP-based regimen 3 (1.8)
  Lop/rit-based regimenc 21 (12.5)
  Triple NRTI regimen using ABC 3 (1.8)
 Number of days between diagnosis and initiation of ART, median (IQR) 13.0 (6.0-26.5)
 ART started within ≤7 days of diagnosisd
  Among all subjects 42 (33.9)
  Among those with advanced disease 29 (37.7)
Co-trimoxazole
 Among all subjectse 83 (52.9)
 Among those with CD4 ≤350 cells/mm3 OR stage 3 or 4 diseasef 77 (64.7)
IPT
 No TB symptoms presentg 77 (46.4)
  Active extra-pulmonary TB 4 (5.2)
  Eligible for IPT: No TB screening symptoms or active TB 73 (44.0)
   INH prescription providedh 1 (1.4)
 TB symptoms present 89 (53.6)
  Diagnostic evaluation performed 35 (39.3)
  Diagnostic evaluation negativei 25 (71.4)
Fluconazole
 CD4 <100 and neurological symptoms present 7 (5.3)
 CD4 <100 and no neurological symptoms presentj 46 (34.6)
  CrAg screening 0 (0)
  Fluconazole prescription provided 0 (0)
  1. aRegimen available for 168 subjects
  2. bIncludes 1 HIV-2 infected subject
  3. cIncludes 18 HIV-2 infected subjects, 1 dually infected subject receiving TB treatment during an ABC stock-out, and 2 HIV-1 infected subjects
  4. dExcluding those with active TB or CM
  5. eData available for 157 subjects
  6. fData available for 151 subjects, of which 119 met criteria
  7. gData available for 166 subjects
  8. hINH provided for 2 weeks
  9. iEligibility for IPT in this scenario is dependent on clinical presentation and likelihood of TB
  10. jAmong non-pregnant subjects ≥18 years of age. Data available for 133 subjects